Big pharma, Partnering

UCB and Neuropore partner for NPT200-11

Posted on 19 January 2015

Tags: , ,

Neuropore Therapies and UCB have entered into a world-wide collaboration and agreement to develop and commercialize therapeutic products aiming at slowing the progression of Parkinson’s disease and related disorders.

This includes NPT200-11, Neuropore’s novel small molecule that targets pathogenic alpha-synuclein which is currently in preclinical development and is expected to enter clinical Phase 1 in 2015.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time


UCB will receive the world-wide exclusive license to develop and commercialize NPT200-11 in all indications. UCB and Neuropore will work together to complete non-clinical studies, and a first Phase 1 study to be initiated in 2015.

UCB will lead all further clinical development, regulatory activities and commercialization.

Neuropore will receive an initial upfront payment of US$20 million and is entitled to potential development, regulatory and sales-based milestones payments, of up to a potential total of US$460 million, in addition to royalties on net sales.

Financial details of the agreement were not disclosed.

For further deal information visit Current Agreements (subscription required)


Scorecard: Top partnering deals by value in 2014

View: Top pharmaceutical companies

View: Top biotech companies

Reports: Browse our extensive deal making report portfolio

Print Friendly, PDF & Email

Leave a Reply